Advancing Biomedical Science

The Laboratory for Clinical Biochemistry Research (LCBR) focuses on understanding risk factors for heart disease, stroke, venous thrombosis, obesity, diabetes, aging, and frailty using a wide variety of assays in population and family-based research settings, particularly in the areas of coagulation, fibrinolysis, thrombosis, inflammation, and immune system function. These results are linked to animal model studies, especially research in murine atherosclerosis

Image of the Colchester Research Facility

Clinical Studies

The Laboratory research portfolio includes molecular and genetic epidemiology family-based genetic research, clinical trials and basic studies using murine models of disease.

Dr. Olson removing samples from one of the LCBR freezers.

Technical Information

The LCBR Faculty and staff has accumulated a vast amount and diverse range of experience working with and developing multitudes of clinical assays, including information regarding Luminex Overview, and Luminex Data by Analyte.

Drs. Cushman and Zakai discussing research


The Laboratory staff have collaborated on a wide variety of clinical studies, clinical trials, and epidemiology studies on local, national, and international scales.

Faculty Spotlight

Dr. Mary Cushman

Cushman involved in research on new associations with galectin-3

Two articles published in late 2017 point out new associations of galectin-3 with vascular diseases. Galectin-3 is an inflammatory marker that also has procoagulant activity. In the ARIC study we reported that higher levels were associated with increased risk of future venous thrombosis in this large general population cohort of over 15,000 people who were middle-aged at baseline. The hazard ratio was modest at 1.55 in the top quintile of values, but a SNP of galectin-3 (C allele of rs4644) was associated with risk, suggesting a new causal mechanism for venous thrombosis. In the REGARDS cohort, we reported galectin-3 in relation to risk of future stroke in this large biracial cohort of over 30,000 people. We found that higher levels were associated with stroke risk over 5 years, but only in younger people (<64 at baseline); the risk very high at a doubling for those with levels in the top quartile. These two papers open up a new line of research on the importance of galectin-3 in vascular-related diseases. We are currently evaluating whether galectin-3 relates to risk of cognitive impairment.

Galectin-3 and venous thromboembolism incidence: ARIC Study

Galectin-3 and the risk of ischemic stroke in REGARDS